BioRestorative Therapies, Inc. (BRTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 303,300 | 25,000 | 233,600 | 89,100 |
| Cost of goods sold | 8,729 | 2,909 | 18,243 | 6,490 |
| Gross profit | 294,571 | 22,091 | 215,357 | 82,610 |
| Research and development | 2,225,882 | 1,714,327 | 1,320,030 | 1,292,182 |
| General and administrative | 1,373,976 | 3,115,298 | 1,182,320 | 1,259,235 |
| Total operating expenses | 3,599,858 | 4,829,625 | 2,502,350 | 2,551,417 |
| Loss from operations | -3,305,287 | -4,807,534 | -2,286,993 | -2,468,807 |
| Other income | 518 | 1,888 | 566 | 911 |
| Interest income | 73,915 | 99,966 | 158,547 | 175,945 |
| Change in fair value of warrant liabilities | 574,591 | -634,119 | 1,036,464 | -1,736,611 |
| Gain on exchange of warrants | - | - | - | - |
| Total other (expense) income | 649,024 | -532,265 | 1,195,577 | -1,559,755 |
| Net loss | -2,656,263 | -5,339,799 | -1,091,416 | -4,028,562 |
| Net loss per share - basic | -0.3 | -0.64 | -0.13 | -0.5 |
| Net loss per share - diluted | -0.3 | -0.64 | -0.13 | -0.5 |
| Weighted average common shares outstanding - basic | 8,740,382 | 8,357,143 | 8,121,499 | 8,121,499 |
| Weighted average common shares outstanding - diluted | 8,740,382 | 8,357,143 | 8,121,499 | 8,121,499 |